mTOR inhibitors (everolimus · temsirolimus)
mTOR inhibitor
Podocyte injury → proteinuria and FSGS.
Tarceva · ERL
EGFR TKI · approved 2004 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An oral EGFR TKI rarely linked to minimal-change-type glomerular disease, AKI, and dehydration from GI toxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Glomerular disease (including minimal-change-type nephrotic syndrome) and acute kidney injury are reported rarely, at the case level; pharmacovigilance data show measurable disproportionality signals for AKI/renal failure (and rare TMA) but no robust trial-based incidence. Reported rate: proteinuria in 3% — Erlotinib-MONOTHERAPY comparator arm of 4 randomized controlled trials in EGFR-mutation-positive advanced NSCLC (Deng 2022, PMID 35985780).Source: Deng et al., BMJ Open 2022
Weeks to months after starting; proteinuria/creatinine typically improve over weeks after discontinuation.
Distilled from: “Weeks to months after starting therapy; proteinuria/creatinine typically improve over weeks after discontinuation in reported cases.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Reversible, ATP-competitive EGFR tyrosine kinase inhibitor that blocks EGFR autophosphorylation and downstream RAS/MAPK and PI3K/AKT proliferative signaling. Used in EGFR-mutant non-small cell lung cancer and (with gemcitabine) advanced pancreatic cancer.
Class-level context for the major non-renal toxicities of the EGFR TKI class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Pulmonary
Pneumonitis, ILD, effusions, hypertension
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Kidney rows of the label's dosage tables
From the ERLOTINIB label (Jun 2024) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Renal † | For severe (CTCAE grade 3 to 4) renal toxicity | Withhold erlotinib tablets *and consider discontinuation |
Everything below is FAERS — adverse events someone chose to report, about 22,936 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
6,759 of 22,936 reports
Reported with hospitalization
3,765 of 22,936 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2,641 of the 22,936 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Erlotinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
mTOR inhibitor
Podocyte injury → proteinuria and FSGS.
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
Clolar · Purine analog
Capillary-leak / SIRS-like AKI and tumor lysis.
Gilotrif · EGFR TKI
Diarrhea-driven prerenal AKI.
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
Blenoxane · Antitumor antibiotic
Renally excreted (~2/3 in urine); half-life rises exponentially below CrCl 25-35 — exposure/clearance issue amplifying pulmonary toxicity, not a direct nephrotoxin.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Erlotinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Erlotinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 45 clinical records among all 68 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.